Projektbeschreibung
Verabreichung von Krebsmedikamenten auf Basis der Nanotechnologie
Prostatakrebs-Patienten entwickeln gegenüber der konventionellen Androgendeprivationstherapie häufig eine Arzneimittelresistenz, die ein Rezidiv zur Folge hat. Das EU-finanzierte Projekt POLAR STAR strebt eine Kombinationstherapie an, die auf mehrere onkogene Signalwege gleichzeitig abzielt und ihnen synergistisch entgegenwirkt. Mithilfe von biokompatiblen Polymer-Nanoträgern, die bereits behördlich zugelassene Komponenten verwenden, möchten die Forschenden eine höhere Effizienz und Spezifität bei der Verabreichung der neuesten Prostatakrebs-Medikamente erreichen und dadurch unerwünschte Wirkungen minimieren. POLAR STAR wird die Nanoträger anhand von fortschrittlichen spektroskopischen Verfahren chemisch und physikalisch charakterisieren und ihre Wirkung anhand von 3D-Prostatagewebe-Modellen anstelle von Tierversuchen bewerten.
Ziel
Prostate cancer (PC) is the fifth leading cause of cancer-related death worldwide. PC often presents in its Multidrug resistant form leaving the patient few survival chances. New approaches are required to overcome resistance-related problems in PC and nanomedicine holds a lot of premises to effectively contribute in this battle. In this frame POLAR STAR aims at the implementation of combination therapy to treat castrate-resistant PC. Our strategy is to exploit innovative nanotechnology to administer contemporarily different therapeutic agents that synergically exert their activity across multiple oncogenic pathways. We plan to use new mixed polymers based on biocompatible cyclodextrins as these building blocks are already FDA approved. Simple organic chemistry is pursued to implement target selectivity and in vivo tracking of the polymeric nanocarrier. The design is guided by the final goal, the future clinical application of nanocarriers to improve PC treatment, keeping in mind upgrade of the nanocarrier systems to large scale production. We will focus on the latest PC drugs suffering from side effects and emerging resistance as multiple cargo to be loaded. Full chemico-physical characterization of the systems is planned as well as assessment of the efficacy of loaded nanocarriers in cell cultures with different drug responsivity profiles. In order to reduce animal experiments POLAR STAR will take full advantage of 3D prostate tissue models for biological tests, an apporach at the forefront in drug design. We plan to reach our goal bringing together the expertise of the fellow and the supervisor supported by the private and academic teams hosting the fellow during secondments. POLAR STAR creates a multidisciplinary environment where all actors, public and private, will benefit from reciprocal transfer of knowledge. During the project the fellow will have the possibility to become a complete researcher improving also complementary skills.
Wissenschaftliches Gebiet
- medical and health sciencesclinical medicineoncologyprostate cancer
- natural scienceschemical sciencesorganic chemistry
- medical and health sciencesbasic medicinemedicinal chemistry
- medical and health sciencesmedical biotechnologynanomedicine
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance
Schlüsselbegriffe
Programm/Programme
Thema/Themen
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenFinanzierungsplan
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Koordinator
00185 Roma
Italien